Dipna Pharmachem Valuation

Is 543594 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543594 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 543594's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 543594's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543594?

Key metric: As 543594 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543594. This is calculated by dividing 543594's market cap by their current earnings.
What is 543594's PE Ratio?
PE Ratio	15.2x
Earnings	₹10.85m
Market Cap	₹165.19m

543594 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.1x
Enterprise Value/EBITDA	6.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 543594's PE Ratio compare to its peers?

The above table shows the PE ratio for 543594 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	28.9x
538874 Nexus Surgical and Medicare	24.8x	n/a	₹99.3m
SAROJA Saroja Pharma Industries India	32.7x	n/a	₹233.0m
542934 Chandra Bhagat Pharma	32.9x	n/a	₹520.6m
MONOPHARMA Mono Pharmacare	25.2x	n/a	₹615.7m
543594 Dipna Pharmachem	15.2x	n/a	₹165.2m

Price-To-Earnings vs Peers: 543594 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the peer average (28.9x).

Price to Earnings Ratio vs Industry

How does 543594's PE Ratio compare vs other companies in the IN Healthcare Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
523696 Fortis Malar Hospitals	2.1x	n/a	US$11.76m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 543594 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the Indian Healthcare industry average (41.9x).

Price to Earnings Ratio vs Fair Ratio

What is 543594's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543594 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 543594's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mohini Health & Hygiene

₹875.3m

Engages in the manufacture and sale of health and hygiene products in India.

MHHL

₹48.00

-4.9%

-28.0%

Dr Lalchandani Labs

₹78.0m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.00

n/a

N G Industries

₹547.0m

Provides various healthcare services in India.

530897

₹163.25

-2.7%

-2.5%